查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球卵巢癌市場
市場調查報告書
商品編碼
1140756

2022-2029 年全球卵巢癌市場

Global Ovarian Cancer Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球卵巢癌市場預計在預測期內（2022-2029 年）將以 16% 的複合年增長率增長。

卵巢癌是一種致命的婦科癌症，在全球女性中排名第七。大多數患有卵巢癌的女性被診斷為晚期，這是最難治療的。化療和手術通常用於治療卵巢癌。

市場動態

主要驅動因素是卵巢癌發病率的上升、技術創新臨床試驗的增加、醫療保健成本的上升、卵巢癌治療中聯合療法的使用以及老年人口的增加。

卵巢癌負擔加重和女性人口老齡化正在推動全球市場的增長。

患病率的上升和女性老年人口的增加正在推動全球市場的增長。例如，根據國際世界癌症研究基金會的數據，卵巢癌是女性中第八大最常見的癌症，也是總體上第十八大□□最常見的癌症。根據美國國立衛生研究院的數據，2020年全球將有超過313,000例卵巢癌新病例和207,252例卵巢癌新死亡病例，使其成為最常見的類型，佔所有卵巢癌的90%或更多。此外，根據美國國立衛生研究院的數據，隨著年齡的增長，女性患卵巢癌的風險會增加，因此越來越多的老年女性正在推動全球市場的增長。例如，到 2020 年，65 歲及以上的人口將達到 7.27 億。女性的壽命比男性長，因此她們佔老年人的大多數。

在卵巢癌方面，癌症治療的成本正在製約全球市場的增長。

然而，癌症治療成本高、卵巢癌缺乏準確診斷以及新興和低收入國家的低意識預計將抑制市場。對於沒有健康保險的患者，晚期癌症的手術和化療費用可能在 20,000 美元到 200,000 美元之間。

全球卵巢癌市場 - 行業分析

《世界卵巢癌報告》根據波特五力、創新、新產品發布、定價和管道分析等各種行業因素對市場進行了深入分析。

細分分析

預測期內（2022-2029年），卵巢癌市場有望以影像檢測市場為主

2021年，上皮性卵巢癌將主導全球市場。由於上皮癌是最常見的卵巢癌類型，預計在整個預測期間（2022-2029 年）將顯示出類似的趨勢。許多臨床研究正在進行中。例如，根據英國癌症研究，100 個卵巢腫瘤中約有 90 個（90%）是上皮腫瘤，根據 ClinicalTrails.Gov. 的增加，已經在上皮腫瘤中進行了 200 多項臨床研究。據 Gov 稱，上皮性卵巢癌有 200 多項介入試驗。一個例子是 HIPEC（腹膜內高溫化療）用於治療復發性卵巢癌、早期復發（小於 3 個月）或一線標準治療的 p53 突變上皮性卵巢癌的 III 期隨機試驗。卡鉑聯合 Wee-1 抑製劑 MK-1775 在晚期疾病患者中的 II 期藥理學試驗。 GINECO II 期研究評估貝伐單抗、奧拉帕尼和 Durvalumab (MEDI 4736) 在復發性晚期上皮性卵巢癌中的安全性和有效性，具有高葉酸受體 Alpha 的鉑耐藥性，高度進展 有許多試驗，包括 3 期試驗Milbetaxin 單藥治療高級別上皮性卵巢癌、原發性腹膜癌和輸卵管癌。

區域分析

預計亞太地區將主導全球卵巢癌市場。

預計亞太地區將主導全球卵巢癌市場，因為它的卵巢癌發病率最高，佔世界人口的大多數。例如，據WHO統計，2020年東亞卵巢癌新增病例71353例，死亡45690例，東南亞卵巢癌新增病例31169例，死亡31169例20012、59730南亞和中亞的卵巢癌新增病例和死亡病例為 41407 例，西亞因卵巢癌進展新增病例為 8507 例，死亡病例為 5827 例。另外，亞太地區是世界上人口最多的國家，印度和中國，比如2021年印度的人口是14.12億，而中國的人口是14.26億，我在這裡。亞太地區佔世界人口的60%，帶動了該地區卵巢癌市場的增長。

競爭格局

在全球卵巢癌市場運營的主要公司有羅氏、葛蘭素史克、阿斯利康、勃林格殷格翰、百時美施貴寶、諾華、新基、安進、輝瑞和默克。領先企業正在採取各種策略，如產品發布、併購、合作夥伴關係和合作，為全球卵巢癌市場的增長做出貢獻。例如，2022 年 8 月 16 日，葛蘭素史克收購了 Affinivax, Inc.。此外，2021 年 12 月 22 日，諾華收購了 Gyroscope Therapeutics。

AstraZeneca plc

概述

AstraZeneca plc 是一家領先的製藥和生物技術公司，服務於癌症、心血管、胃腸道、傳染病、神經科學、呼吸和炎症。 AstraZeneca plc 成立於 1999 年，總部位於英國劍橋。

產品組合

AstraZeneca plc的卵巢癌產品組合包括 LYNPARZA。

全球卵巢癌報告將提供對大約 40 多個市場數據表、45 多個圖表和 200 多頁（大約）的訪問。

內容

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 卵巢癌負擔不斷上升
      • 老年女性人口增加
    • 抑制因素
      • 高成本
      • 缺乏治療選擇
    • 商機
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 上皮性卵巢癌
  • 生殖細胞卵巢癌
  • 基質細胞卵巢癌
  • 小細胞卵巢癌

第 8 章按治療類型

  • 靶向治療
  • 手術治療
  • 化療
  • 免疫療法
  • 其他

第 9 章按診斷類型

  • 驗血
  • 圖像檢查
  • 腹腔鏡檢查
  • 結腸鏡檢查
  • 其他

第 10 章藥物類別

  • PARP抑製劑
  • 血管生成抑製劑
  • PD-L1抑製劑

第 11 章最終用戶

  • 醫院和診所
  • 診斷中心
  • 癌症研究中心
  • 其他

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 14 章公司簡介

  • AstraZeneca
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Roche
  • GlaxoSmithKline
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Novartis
  • Celgene
  • Amgen
  • Pfizer
  • Merck

第 15 章 DataM

簡介目錄
Product Code: DMPH2179

Market Overview

Ovarian Cancer Market was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 16% during the forecast period (2022-2029).

Ovarian cancer is the deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.

Market Dynamics

The major driving forces are rising ovarian cancer incidence, a growing number of clinical trials for innovations, increasing health expenditure, the use of combination therapies to treat ovarian cancer, and an increasing geriatric population.

The increasing burden of ovarian cancer and the growing female geriatric population drive global market growth.

The growing prevalence and female geriatric population are fueling the global market growth. For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall. As per the NIH, there were more than 313,000 new cases of ovarian cancer in 2020, and a total of 207,252 new deaths from ovarian cancer were reported globally; ovarian carcinoma is the most common type of ovarian cancer, comprising over 90% of all ovarian cancer cases. Furthermore, according to the NIH, the risk of ovarian cancer increases in females with age; therefore, the growing female geriatric population drives the global market growth. For instance, 727 million persons aged 65 years or over in 2020. Since women live longer than men, they comprise the majority of older persons, especially at advanced ages.

The costly cancer treatment is restraining the global Ovarian Cancer growth.

However, the high cost of cancer treatment, lack of accurate diagnosis of ovarian cancer, and lack of awareness in emerging and low-income economies are expected to restrain the market. For patients without health insurance, the cost ranges from $20,000 to $200,000 or more for treatment with surgery and chemotherapy for advanced cancer.

Global Ovarian Cancer Market-Industry analysis.

The global ovarian cancer report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, pipeline analysis Etc.

Segment Analysis

The imaging test market is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)

Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more.

Geographical Analysis

The Asia Pacific is expected to command dominating the global ovarian cancer market.

The Asia Pacific is predicted to command the global ovarian cancer market since the Asia Pacific has the highest prevalence of ovarian cancer and the largest portion of the global population. For instance, according to the statistics from the WHO, in 2020, Eastern Asia had 71 353 new cases and 45 690 deaths due to ovarian cancer, South-Eastern Asia had 31 169 new cases and 20 012 deaths because of ovarian cancer, South-Central Asia had 59 730 new cases and 41 407 deaths of ovarian cancer patients while Western Asia had 8 507 new cases and 5 827 deaths as a result of ovarian cancer advancement. Furthermore, the Asia Pacific has the highest populated countries in the world, India and China; for instance, in 2021, India's population was 1.412 billion, compared to China's 1.426 billion. The Asia Pacific accounts for 60% of the global population, fueling the ovarian cancer market growth in this region.

Competitive Landscape

The key players operating in the global ovarian cancer market are Roche, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Celgene, Amgen, Pfizer, and Merck. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the ovarian cancer market globally. For instance, on 16 August 2022, GSK acquired Affinivax, Inc. Also, on December 22, 2021, Novartis acquired Gyroscope Therapeutics.

AstraZeneca plc

Overview:

AstraZeneca plc is a leading pharmaceutical and biotechnology company dealing with oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. AstraZeneca plc was founded in 1999 and is headquartered in Cambridge, UK.

Product Portfolio:

The product portfolio of AstraZeneca plc for ovarian cancer has LYNPARZA.

The global ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Burden of Ovarian Cancer
      • 4.1.1.2. Rising Female Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost
      • 4.1.2.2. Lack of Treatment Options
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Epithelial Ovarian Cancer
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Germ Cell Ovarian Cancer
  • 7.4. Stromal Cell Ovarian Cancer
  • 7.5. Small Cell Ovarian Cancer

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 8.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 8.2. Targeted Therapy
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Surgery
  • 8.4. Chemotherapy
  • 8.5. Immunotherapy
  • 8.6. Others

9. By Diagnosis Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type Segment
    • 9.1.2. Market Attractiveness Index, By Diagnosis Type Segment
  • 9.2. Blood Tests
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Imaging Tests
  • 9.4. Laparoscopy
  • 9.5. Colonoscopy
  • 9.6. Others

10. By Drug class

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 10.1.2. Market Attractiveness Index, By Drug Class Segment
  • 10.2. PARP Inhibitors
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Angiogenesis Inhibitors
  • 10.4. PD-L1 Inhibitors

11. By End User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 11.1.2. Market Attractiveness Index, By End User Segment
  • 11.2. Hospitals And Clinics
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Diagnostic Centers
  • 11.4. Cancer Research Centers
  • 11.5. Other

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. The U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking

14. Company Profiles

  • 14.1. AstraZeneca
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Roche
  • 14.3. GlaxoSmithKline
  • 14.4. Boehringer Ingelheim
  • 14.5. Bristol-Myers Squibb
  • 14.6. Novartis
  • 14.7. Celgene
  • 14.8. Amgen
  • 14.9. Pfizer
  • 14.10. Merck

LIST NOT EXHAUSTIVE

15. DataM

  • 15.1. Appendix
  • 15.2. About Us and Services
  • 15.3. Contact Us